GlassScriptPhysician profile
Nancy Maxey-Norris
NPI 1083065932
$3,368.82
in general payments reported to CMS, 2019-2025
24 companies · $1,310 in 2025
The $1,310 reported for 2025 was more than what 90% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $332 · 2022: $434 · 2023: $260 · 2024: $1,033 · 2025: $1,310.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,603.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,603.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $561.53 | 2024-2025 | Tremfya, Stelara |
| Astrazeneca Pharmaceuticals LP | $480.03 | 2021-2025 | Airsupra, Breztri |
| Axsome Therapeutics, INC. | $351.65 | 2024-2025 | Auvelity, Symbravo |
| Alexion Pharmaceuticals, INC. | $262.92 | 2022-2023 | Ultomiris |
| Optinose US, INC. | $124.99 | 2024 | |
| Grifols USA, LLC | $124.98 | 2022 | |
| Vanda Pharmaceuticals INC. | $124.98 | 2025 | Fanapt |
| Lundbeck LLC | $124.98 | 2024 | Vyepti |
| E.R. Squibb & Sons, L.L.C. | $122.09 | 2025 | Cobenfy |
| Genentech USA, INC. | $121.83 | 2024 | Xolair |
| Glaxosmithkline, LLC. | $121.83 | 2024 | Arexvy |
| Regeneron Healthcare Solutions, INC. | $121.82 | 2023 | Dupixent |
| Neurocrine Biosciences, INC. | $98.71 | 2025 | |
| Silk Road Medical, INC. | $95.71 | 2024 | Enroute Transcarotid Neuroprotection System, Enroute Transcarotid Stent, Enroute Enflate Transcarotid Rx Balloon Dilatation Catheter |
| Paratek Pharmaceuticals, INC. | $86.58 | 2025 | Nuzyra |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axonics, INC. | $84.39 | 2021 | |
| Sage Therapeutics, LLC | $72.50 | 2024-2025 | Zurzuvae |
| Shield Therapeutics INC | $65.04 | 2023-2025 | Accrufer |
| Idorsia Pharmaceuticals US INC | $59.43 | 2022 | |
| Novo Nordisk INC | $57.51 | 2021 | |
| Esperion Therapeutics, INC. | $51.66 | 2021 | |
| Acera Surgical, INC. | $22.57 | 2025 | Restrata Wound Matrix |
| Pfizer INC. | $18.13 | 2024 | |
| Medtronic, INC. | $12.96 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nancy Maxey-Norris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.